Close Menu
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    BusinessNewsAsia.comBusinessNewsAsia.com
    Subscribe
    • Home
    • Top Stories
    • Business
    • Tech
    • Companies
    • Events
    • Announcements
    BusinessNewsAsia.comBusinessNewsAsia.com
    Home»Venture Capital»SoftBank Vision Fund Anchors $400m Series C Funding in Relay Therapeutics
    Venture Capital

    SoftBank Vision Fund Anchors $400m Series C Funding in Relay Therapeutics

    Business News AsiaBy Business News AsiaDecember 20, 2018No Comments1 Min Read
    Share
    Facebook Twitter LinkedIn Pinterest Email

    SoftBank Vision Fund, a subsidiary of Japan’s SoftBank Group Co, has led the $400-million Series C funding round in US-based biotechnology firm Relay Therapeutics, according to a statement Thursday. The financing round was also participated by Foresite Capital, Perceptive Advisors, and Tavistock Group. Existing GV, Casdin Capital, BVF Partners, EcoR1 Capital, Alexandria Venture Investments, and an affiliate of D.E. Shaw Research also backed the round. Proceeds from this financing are anticipated to be used to accelerate the implementation of Relay Therapeutics’ long-term strategy. Relay said the fresh funds will support the expansion of the company’s discovery efforts, advance existing programs into the clinic and bolster its broad platform and diverse team. Read full story at AsiaPEVC.com

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleInter-regional Collaboration Explored at Lifestyle Expo
    Next Article JCB Launches QR Code Payment in the Asian Region

    Related Posts

    Central Asia visit momentum continues as Alatau City investment promotion event held in Hong Kong

    June 11, 2026

    HKTDC’s ‘Hong Kong Tech Pavilion’ at Paris VivaTech 2026 to showcase 24 Hong Kong startups to connect global investment opportunities

    June 7, 2026

    Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion

    June 4, 2026
    Add A Comment

    Comments are closed.

    © 2026 BusinessNewsAsia.com
    • About Us
    • Contact Us
    • BusinessNews.ph
    • AsiaPEVC.com
    • DevFiNews.com
    • RenewableEnergy.ph

    Type above and press Enter to search. Press Esc to cancel.